Free Trial
NASDAQ:SCYX

SCYNEXIS Q1 2024 Earnings Report

SCYNEXIS logo
$0.68 -0.01 (-1.30%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$0.71 +0.03 (+4.68%)
As of 08/1/2025 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SCYNEXIS EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.18
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

SCYNEXIS Revenue Results

Actual Revenue
$1.37 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

SCYNEXIS Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Wednesday, May 8, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

SCYNEXIS' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025

SCYNEXIS Earnings Headlines

Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
Scynexis to present preclinical data on SCY-247 at ESCMID Meeting
See More SCYNEXIS Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SCYNEXIS? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SCYNEXIS and other key companies, straight to your email.

About SCYNEXIS

SCYNEXIS (NASDAQ:SCYX), a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

View SCYNEXIS Profile

More Earnings Resources from MarketBeat